Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.61 |
| ▸ | PPARD | Q03181 | 11/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL814804 | 0.89 | ABCG2 (0.50) | PPARAPPARDPPARGABCG2CXCL12 | |
| SCHEMBL13359189 | 0.88 | MAOB (0.61) | PPARAPPARDPPARGKCNH2 | |
| SCHEMBL814554 | 0.87 | PPARA (0.61) | PPARAPPARDPPARGABCG2KCNH2 | |
| SCHEMBL814790 | 0.86 | PPARA (0.67) | PPARAPPARDPPARGABCG2KCNH2 | |
| SCHEMBL815466 | 0.83 | APP (0.57) | PPARAPPARDABCG2CXCL12AR | |
| SCHEMBL814530 | 0.82 | PPARA (0.75) | PPARAPPARDPPARGKCNH2 | |
| SCHEMBL814528 | 0.82 | ABCG2 (0.62) | ABCG2CXCL12ARMEN1NPC1 | |
| SCHEMBL3249049 | 0.82 | ABCG2 (0.62) | ABCG2CXCL12ARMEN1NPC1 | |
| SCHEMBL4462406 | 0.82 | PPARA (0.69) | PPARAPPARDPPARGABCG2KCNH2 | |
| SCHEMBL11893175 | 0.82 | PPARA (0.69) | PPARAPPARDPPARGABCG2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461212-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2013-06-11 | — | — | US | disclosed |
| US-8461212-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2012-05-24 | — | — | US | disclosed |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2012-05-24 | — | — | US | disclosed |
| US-8106097-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2012-01-31 | — | — | US | disclosed |
| US-8106097-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2012-01-31 | — | — | US | disclosed |
| US-8058308-B2 | Substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2011-11-15 | — | — | US | disclosed |
| US-20110190515-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190515-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2011-08-04 | — | — | US | disclosed |
| US-7943661-B2 | Antiischemic agents; for example 1-[2-hydroxy-4-chlorophenyl]-3-[4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one; display peroxisome proliferator activated receptor (PPAR) activator, antioxidant and antiinflammatory properties | GENFIT (FR) | 2011-05-17 | — | — | US | disclosed |
| US-7943661-B2 | Antiischemic agents; for example 1-[2-hydroxy-4-chlorophenyl]-3-[4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one; display peroxisome proliferator activated receptor (PPAR) activator, antioxidant and antiinflammatory properties | GENFIT (FR) | 2011-05-17 | — | — | US | disclosed |
| US-20100120909-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2010-05-13 | — | — | US | disclosed |
| US-20100120909-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2010-05-13 | — | — | US | disclosed |
| US-7632870-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2009-12-15 | — | — | US | disclosed |
| US-7632870-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2009-12-15 | — | — | US | disclosed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | disclosed |
| US-7385082-B2 | Preparation of 1,3-diphenylprop-2-en-1-one derivatives | GENFIT (FR) | 2008-06-10 | — | — | US | disclosed |
| US-7385082-B2 | Preparation of 1,3-diphenylprop-2-en-1-one derivatives | GENFIT (FR) | 2008-06-10 | — | — | US | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | PSEN1, BACE1, PSEN2 | PPARA 69/4885PPARD 39/4885PPARG 17/4885 |
| US-20110190515-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | PGF, PTGS1, PTGES3 | PPARA 136/4885PPARD 120/4885PPARG 89/4885 |
| US-20100120909-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | BRCA1, COL1A1, APOL1 | PPARA 112/4885PPARD 193/4885PPARG 119/4885 |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | BRCA1, COL1A1, APOL1 | PPARA 112/4885PPARD 193/4885PPARG 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.